Psychedelics
Unlocking the Potential of Psychedelics for Postpartum Depression
Greg Mayes, J.D.
Reunion Neuroscience
PAO-03-25-CL-05Mar 31, 2025
Proof-of-Concept Trial
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
PR-M11-20-014Nov 18, 2020
Clinical Trials
Haima Therapeutics Receives Phase II TVSF Award from the State of Ohio to Develop its SynthoPlate Product for Veterinary Use
Haima Therapeutics
PR-M07-20-NI-014Jul 10, 2020
Clinical Results
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
VistaGen Therapeutics
PR-M11-19-NI-019Nov 19, 2019
Endpoints
Sanifit Announces the Phase 2b CaLIPSO Trial of SNF472 Met Endpoint in Slowing the Cardiovascular Calcification in Patients on Hemodialysis
Nice Insight
PR-M10-19-NI-051Nov 01, 2019
Positive Results
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® Studies In Pediatric Patients
Amgen
PR-M09-19-NI-056Sep 27, 2019
Phase II
Hovione Announces Successful End-of-Phase 2 Meeting with the FDA and Outlines Phase 3 Program for Minocycline Topical Gel
Hovione
PR-M09-19-NI-047Sep 20, 2019
Clinical Trials
SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial
SELLAS Life Sciences Group
PR-M04-18-NI-020-4444Apr 05, 2018
Clinical Trials
MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis
MediciNova
PR-M04-18-NI-014Apr 04, 2018
Clinical Trials
AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks
AbbVie
PR-M02-18-NI-83Feb 22, 2018
Clinical Trials
BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC
BerGenBio ASA
PR-M01-18-NI-035Jan 12, 2018
Innovation
Regenerating Knee Cartilage with Stem Cells
Nigel Walker
Nice Insight
PAO-M07-17-NI-020Jul 18, 2017